155 related articles for article (PubMed ID: 15026791)
1. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
[TBL] [Abstract][Full Text] [Related]
2. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
3. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
[TBL] [Abstract][Full Text] [Related]
4. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Nelson A; Fenlon D; Morris J; Sampson C; Harrop E; Murray N; Wheatley D; Hood K; Griffiths G; Barrett-Lee P
Trials; 2013 Oct; 14():325. PubMed ID: 24107437
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
Hoskin P; Sundar S; Reczko K; Forsyth S; Mithal N; Sizer B; Bloomfield D; Upadhyay S; Wilson P; Kirkwood A; Stratford M; Jitlal M; Hackshaw A
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26242893
[TBL] [Abstract][Full Text] [Related]
6. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.
Ross JR; Saunders Y; Edmonds PM; Patel S; Broadley KE; Johnston SR
BMJ; 2003 Aug; 327(7413):469. PubMed ID: 12946966
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.
Halvorson KG; Sevcik MA; Ghilardi JR; Sullivan LJ; Koewler NJ; Bauss F; Mantyh PW
J Pain Symptom Manage; 2008 Sep; 36(3):289-303. PubMed ID: 18411018
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid and ibandronate-induced nephrotoxicity in 2D and 3D proximal tubule cells derived from human and rat.
Valencia LJ; Tseng M; Chu ML; Yu L; Adedeji AO; Kiyota T
Toxicol Sci; 2024 Feb; 198(1):86-100. PubMed ID: 38059598
[TBL] [Abstract][Full Text] [Related]
10. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
11. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy.
Yang HL; Liu T; Wang XM; Xu Y; Deng SM
Eur Radiol; 2011 Dec; 21(12):2604-17. PubMed ID: 21887484
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
14. Bone Metastasis in Bladder Cancer.
Yi L; Ai K; Li X; Li Z; Li Y
J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675715
[TBL] [Abstract][Full Text] [Related]
15. Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update.
Chen YH; Ho UC; Kuo LT
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267658
[TBL] [Abstract][Full Text] [Related]
16. All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma.
Brozovich A; Garmezy B; Pan T; Wang L; Farach-Carson MC; Satcher RL
J Bone Oncol; 2021 Dec; 31():100399. PubMed ID: 34745857
[TBL] [Abstract][Full Text] [Related]
17. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
18. Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.
Argentiero A; Solimando AG; Brunetti O; Calabrese A; Pantano F; Iuliani M; Santini D; Silvestris N; Vacca A
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470608
[TBL] [Abstract][Full Text] [Related]
19. Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study.
Wilson C; Martin C; Winter MC
J Bone Oncol; 2019 Apr; 15():100226. PubMed ID: 30937280
[TBL] [Abstract][Full Text] [Related]
20. Role of Bisphosphonates in Breast Cancer Therapy.
Goldvaser H; Amir E
Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
